Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.45 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330030 | 0.92 | ROCK2 (0.46) | ROCK2ABL1ALDH1A1MEN1PKM | |
| SCHEMBL14245038 | 0.84 | ROCK2 (0.64) | ROCK2ABL1ALDH1A1MEN1PKM | |
| SCHEMBL28832884 | 0.84 | ROCK2 (0.53) | ROCK2ABL1ALDH1A1MEN1PKM | |
| SCHEMBL2440169 | 0.82 | ROCK2 (0.55) | ROCK2LMNA | |
| SCHEMBL12330028 | 0.81 | ROCK2 (0.48) | ROCK2ALDH1A1MAPK1LMNACYP17A1 | |
| SCHEMBL14245264 | 0.81 | ROCK2 (0.51) | ROCK2ABL1ALDH1A1MEN1PKM | |
| SCHEMBL12330029 | 0.80 | ROCK2 (0.49) | ROCK2ALDH1A1MAPK1LMNACYP17A1 | |
| SCHEMBL4518862 | 0.78 | ROCK2 (0.47) | ROCK2ALDH1A1MEN1PKMKMT2A | |
| SCHEMBL2439543 | 0.78 | KDM4E (0.46) | ROCK2ALDH1A1MEN1PKMKMT2A | |
| SCHEMBL12329645 | 0.77 | ROCK2 (0.44) | ROCK2ALDH1A1MAPK1LMNACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ABL1 499/4885ALDH1A1 2624/4885 |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ABL1 539/4885ALDH1A1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.